Ascendis Pharma stock target raised to $245 by JPMorgan

Published 02/05/2025, 16:36
Ascendis Pharma stock target raised to $245 by JPMorgan

On Friday, JPMorgan maintained a positive stance on Ascendis Pharma (NASDAQ:ASND) shares by increasing the price target to $245 from the previous $200, while keeping an Overweight rating on the stock. The adjustment follows the company’s first-quarter results, which surpassed expectations, and subsequent discussions with management. Currently trading at $171, the stock is near its 52-week high of $173, with analyst targets ranging from $168 to $293. According to InvestingPro analysis, the stock appears fairly valued based on its proprietary Fair Value model.

Ascendis Pharma’s revenue from Yorvipath™ reached €44.7 million, approximately 50% higher than JPMorgan’s estimates and consensus figures. The performance of Yorvipath™, a key product for the company, has instilled further confidence in its growth potential. In light of these developments, JPMorgan’s analysts have revised their worldwide sales forecasts for Yorvipath™ for the years 2025 to 2030, increasing them by 27-53%. InvestingPro data reveals impressive revenue growth of 36.34% over the last twelve months, with exceptional gross profit margins of 87.83%. For deeper insights into Ascendis Pharma’s financial health and growth prospects, explore the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.

The analyst, representing JPMorgan, expressed increased conviction in the trajectory of Yorvipath™, citing the strong revenue figures as a driver for potential continued appreciation in Ascendis Pharma’s stock value. The substantial revision of the sales estimates reflects the analyst’s belief in the long-term success of Yorvipath™ in the market. This optimism is supported by the stock’s strong performance, with a 33.68% return over the past six months.

Ascendis Pharma specializes in creating innovative therapies and has been closely monitored by investors for its growth prospects. The company’s latest financial results and the positive outlook from analysts may influence investor sentiment and market performance of its shares.

The revised price target of $245 indicates JPMorgan’s expectation of Ascendis Pharma’s stock reaching new heights, driven by the strong performance and market adoption of Yorvipath™. This new target represents a significant increase from the prior target and underscores the firm’s confidence in the company’s future financial success.

In other recent news, Ascendis Pharma has seen several analyst updates reflecting strong performance and future potential. Evercore ISI has raised its price target for Ascendis Pharma to $280, citing a robust first quarter with significant prescription growth and successful transitions to paid drug conversions. RBC Capital has initiated coverage with an Outperform rating and a price target of $205, highlighting Ascendis Pharma’s advantageous market position and the potential for its Yorvipath to surpass sales expectations. UBS maintains a Buy rating with a $196 target, anticipating strong sales for Yorvipath and noting the company’s progress toward profitability by 2025 and 2026.

Cantor Fitzgerald has also increased its target to $200, following better-than-expected fourth-quarter earnings for 2024 and impressive prescription numbers for Yorvipath. Despite an expected rise in operating expenses, Cantor Fitzgerald remains optimistic about Ascendis Pharma’s growth trajectory. Additionally, Evercore ISI had previously raised its target to $260, expressing confidence in the company’s potential for significant value growth in 2025 and beyond. These developments indicate a positive outlook from analysts, who are closely monitoring Ascendis Pharma’s progress and strategic initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.